Health‐Related Quality of Life Measures in Adult Systemic Lupus Erythematosus

Izadi, Zara

doi:10.1002/acr.24245

Cited by 9 publications

(7 citation statements)

References 86 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We advise physicians to discuss sexual health in all men with SLE, focusing on patients' experiences and expectations, and not merely on disease scores, which do not reflect patient-centred outcomes. 33,34 This study demonstrates that alterations in sexual function in men with SLE are not uncommon and are related to lower HRQoL, and that they can be easily identified by the use of a single question. This question can be used to determine which patients could benefit from a multidisciplinary intervention aimed at providing the best pharmacological or non-pharmacological treatment to improve sexual function.…”

Section: Discussionmentioning

confidence: 74%

Determinants of sexual function in male patients with systemic lupus erythematosus

Campos-Guzmán

Valdez-López

Govea‐Pelaéz

et al. 2022

Lupus

View full text Add to dashboard Cite

Objectives Our study aims to describe the association between SLE and sexual function, analysing demographic variables, comorbidities and other disease-related factors. As an exploratory objective, the impact of asking about sexual function during outpatient consultation was evaluated. Methods From 2018 to 2019, we invited sexually active men diagnosed with SLE to complete questionnaires that evaluated their sexual function and quality of life. Additionally, patients were asked if they believed they had sexual dysfunction, whether they would be interested in receiving specialized sexual care, and if they considered SLE to be detrimental to their sexual function. Epidemiological and disease-related data were retrieved from the patients’ clinical records. Results We included 124 men with SLE. Twenty-two (18%) patients answered positively when asked if they believed they had sexual dysfunction. These patients had lower overall erectile function scores and lower physical function scores than those who did not consider they had sexual dysfunction. In the multivariable analysis, factors that were associated with better sexual function were high physical function (B = 0.126, p = .031), lower BMI (B = 0.53, p = .010) and the patient’s perception of normal sexual function (B = 13.0, p < .001). Comorbidities associated with worse sexual function were type 2 diabetes (B = −8.1, p = .017) and a history of thrombosis (B = −5.12, p = .019). Conclusion Sexual function of male patients with SLE is impaired, independently of disease activity, chronic disease damage or pharmacological treatment. A simple question about perception of sexual function in the outpatient clinic can be used to help determine which patients could benefit from a multidisciplinary intervention to improve sexual health.

show abstract

Section: Discussionmentioning

confidence: 74%

Determinants of sexual function in male patients with systemic lupus erythematosus

Campos-Guzmán

Valdez-López

Govea‐Pelaéz

et al. 2022

Lupus

View full text Add to dashboard Cite

show abstract

“…Our study has some limitations. First, we used items from the SF-36 questionnaire to assess fatigue and depression, and not more speci c questionnaires dedicated to SLE patients (such as SLEQOL, LIT, L-QOL, LupusQOL, LupusPRO) (25). However, the SF-36 has been used for a long time and more widely than speci c scales and it is well validated in SLE (26) and widely available, even retrospectively, in SLE cohorts.…”

Section: Discussionmentioning

confidence: 99%

Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures

et al. 2023

View full text Add to dashboard Cite

Patients with systemic lupus erythematosus (SLE) display symptoms that are not always related to disease activity and may distort clinical trial results. Recently, a clinical categorization based on the presence of type 1 (in ammatory manifestations) and/or type 2 (widespread pain, fatigue, depression) symptoms has been proposed in SLE. Our aim was to develop a type 2 score derived from the Short-Form health survey (SF-36) to categorize SLE patients and to compare immunological and transcriptomic pro les between groups. MethodsSeventeen items from the SF-36 were selected to build a type 2 score for 50 SLE patients (100 visits; LUPUCE cohort) and the SLEDAI was used to de ne type 1 symptoms. Patients were categorized in four groups: minimal (no symptoms), type 1, type 2 and mixed (both type 1 and type 2 symptoms). Clinical, immunological and transcriptomic pro les were compared between the groups. ResultsType 2 scores ranged from 0 to 31, with a cut-off value of 14 (75th percentile). The sample categorization was: minimal in 39%, type 1 in 37%, type 2 in 9% and mixed in 15%. Type 2 patients were older than minimal patients and had a longer disease duration than type 1 and mixed patients. Immunological data and modular interferon signatures did not differ between the groups. ConclusionPatients with SLE can be categorized into four clinical groups using the SLEDAI score and our SF-36derived type 2 score. This categorization is non-redundant with immunological or transcriptomic pro les and could prove useful to stratify patients in clinical trials. Signi cance And InnovationsA score derived from selected items of the SF-36 can be used to identify SLE patients with type 2 symptoms according to the Duke University categorization.Using the SLEDAI and this type 2 score, SLE patients can be categorized in four clinical groups. This categorization is not related to immunological activity or blood transcriptome pro les (and not to the interferon signature in particular).

show abstract

“…The total score ranges from 40 to 280, with good quality of life scoring lowest. SLEQOL has six domains, namely, physical functioning (questions 1-6), activities (questions 7-15), symptoms (questions [16][17][18][19][20][21][22][23], treatment (questions [24][25][26][27], mood (questions [28][29][30][31], and self-image (questions 32-40). 17 The SF-36 is a 36-item generic QoL questionnaire.…”

Section: Data Collectionmentioning

confidence: 99%

“…[8][9][10][11][12][13][14][15][16] Meanwhile, SLE-specific QoL instruments have also been introduced: SLEQOL, LupusQol, L-Qol, and LupusPRO. [17][18][19][20][21] Initially, investigators concentrated on establishing cross-sectional rather than longitudinal validity; 22 preliminary work suggests that SLEQOL is more sensitive to change than SF-36 whereas LupusQol is equivalent. 17,23 A paper published in 2018 concluded that SLEspecific QoL questionnaires (LupusPRO, LupusQol, and SLEQOL) demonstrated greater responsiveness than the domains of SF-36.…”

Section: Introductionmentioning

confidence: 99%

“…In the past 20 years, the generic QoL instrument MOS 36‐Item Short‐Form Health Survey (SF‐36) has been widely used in SLE studies 8–16 . Meanwhile, SLE‐specific QoL instruments have also been introduced: SLEQOL, LupusQol, L‐Qol, and LupusPRO 17–21 . Initially, investigators concentrated on establishing cross‐sectional rather than longitudinal validity; 22 preliminary work suggests that SLEQOL is more sensitive to change than SF‐36 whereas LupusQol is equivalent 17,23 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medications impact different aspects of the quality of life of patients with systemic lupus erythematosus

et al. 2022

View full text Add to dashboard Cite

Purpose In this real‐world observational study, we analyzed the effects of different drugs on the quality of life (QoL) of patients with systemic lupus erythematosus (SLE). Method We identified patients in our prospective SLE Registry who received new medications. We measure QoL with MOS 36‐Item Short‐Form Health Survey (SF‐36), a generic health questionnaire, and SLEQOL, a disease‐specific instrument. We compared the patients' scores before and after initiation of treatment. Results We identified 259 episodes of drug initiation in 193 SLE patients. SLEQOL registered statistically significant changes with intravenous cyclophosphamide (total score and the domains of physical functioning, activities, and self‐image), mycophenolate (total score, treatment, mood, and self‐image) and azathioprine (total score, activities, and mood), but not with cyclosporin A and hydroxychloroquine. Two SF‐36 subscales (general health and physical functioning) showed statistically significant improvement in the patients who received intravenous cyclophosphamide. Both instruments have floor effect. There was weak correlation between changes in the QoL instruments and the patient assessment of disease activity or an objective disease activity index. Conclusion SLEQOL distinguishes the differential effects on QoL of the various drugs. Treatment with intravenous cyclophosphamide and mycophenolate impacted the highest numbers of domains of SLEQOL, followed by azathioprine, cyclosporin A, and hydroxychloroquine. SLEQOL may be a useful outcome measure in SLE clinical trials.

show abstract

Health‐Related Quality of Life Measures in Adult Systemic Lupus Erythematosus

Cited by 9 publications

References 86 publications

Determinants of sexual function in male patients with systemic lupus erythematosus

Determinants of sexual function in male patients with systemic lupus erythematosus

Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures

Medications impact different aspects of the quality of life of patients with systemic lupus erythematosus

Contact Info

Product

Resources

About